BACKGROUND: Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-blood transplantation. We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells. METHODS: We studied engraftment results in 31 adults with hematologic cancers who received transplants of 2 cord-blood units, 1 of which contained cord blood that was expanded ex vivo in cocultures with allogeneic mesenchymal stromal cells. The results in these patients were compared with those in 80 historical controls who received 2 units of unmanipulated cord blood. RESULTS: Coculture with mesenchymal stromal cells led to an expansion of total nucleated cells by a median factor of 12.2 and of CD34+ cells by a median factor of 30.1. With transplantation of 1 unit each of expanded and unmanipulated cord blood, patients received a median of 8.34×10(7) total nucleated cells per kilogram of body weight and 1.81×10(6) CD34+ cells per kilogram--doses higher than in our previous transplantations of 2 units of unmanipulated cord blood. In patients in whom engraftment occurred, the median time to neutrophil engraftment was 15 days in the recipients of expanded cord blood, as compared with 24 days in controls who received unmanipulated cord blood only (P<0.001); the median time to platelet engraftment was 42 days and 49 days, respectively (P=0.03). On day 26, the cumulative incidence of neutrophil engraftment was 88% with expansion versus 53% without expansion (P<0.001); on day 60, the cumulative incidence of platelet engraftment was 71% and 31%, respectively (P<0.001). CONCLUSIONS: Transplantation of cord-blood cells expanded with mesenchymal stromal cells appeared to be safe and effective. Expanded cord blood in combination with unmanipulated cord blood significantly improved engraftment, as compared with unmanipulated cord blood only. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00498316.).
BACKGROUND: Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-blood transplantation. We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells. METHODS: We studied engraftment results in 31 adults with hematologic cancers who received transplants of 2 cord-blood units, 1 of which contained cord blood that was expanded ex vivo in cocultures with allogeneic mesenchymal stromal cells. The results in these patients were compared with those in 80 historical controls who received 2 units of unmanipulated cord blood. RESULTS: Coculture with mesenchymal stromal cells led to an expansion of total nucleated cells by a median factor of 12.2 and of CD34+ cells by a median factor of 30.1. With transplantation of 1 unit each of expanded and unmanipulated cord blood, patients received a median of 8.34×10(7) total nucleated cells per kilogram of body weight and 1.81×10(6) CD34+ cells per kilogram--doses higher than in our previous transplantations of 2 units of unmanipulated cord blood. In patients in whom engraftment occurred, the median time to neutrophil engraftment was 15 days in the recipients of expanded cord blood, as compared with 24 days in controls who received unmanipulated cord blood only (P<0.001); the median time to platelet engraftment was 42 days and 49 days, respectively (P=0.03). On day 26, the cumulative incidence of neutrophil engraftment was 88% with expansion versus 53% without expansion (P<0.001); on day 60, the cumulative incidence of platelet engraftment was 71% and 31%, respectively (P<0.001). CONCLUSIONS: Transplantation of cord-blood cells expanded with mesenchymal stromal cells appeared to be safe and effective. Expanded cord blood in combination with unmanipulated cord blood significantly improved engraftment, as compared with unmanipulated cord blood only. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00498316.).
Authors: M J Laughlin; J Barker; B Bambach; O N Koc; D A Rizzieri; J E Wagner; S L Gerson; H M Lazarus; M Cairo; C E Stevens; P Rubinstein; J Kurtzberg Journal: N Engl J Med Date: 2001-06-14 Impact factor: 91.245
Authors: Claudio G Brunstein; Jonathan A Gutman; Daniel J Weisdorf; Ann E Woolfrey; Todd E Defor; Theodore A Gooley; Michael R Verneris; Frederick R Appelbaum; John E Wagner; Colleen Delaney Journal: Blood Date: 2010-08-04 Impact factor: 22.113
Authors: Marcos De Lima; Lisa S St John; Eric D Wieder; Ming S Lee; John McMannis; Safa Karandish; Sergio Giralt; Miroslav Beran; Daniel Couriel; Martin Korbling; Samer Bibawi; Richard Champlin; Krishna V Komanduri Journal: Br J Haematol Date: 2002-12 Impact factor: 6.998
Authors: Elizabeth J Shpall; Ralph Quinones; Roger Giller; Chan Zeng; Anna E Baron; Roy B Jones; Scott I Bearman; Yago Nieto; Brian Freed; Nancy Madinger; Christopher J Hogan; Vicki Slat-Vasquez; Peggy Russell; Betsy Blunk; Deborah Schissel; Elaine Hild; Janet Malcolm; William Ward; Ian K McNiece Journal: Biol Blood Marrow Transplant Date: 2002 Impact factor: 5.742
Authors: Manuel N Fernández; Carmen Regidor; Rafael Cabrera; José A García-Marco; Rafael Forés; Isabel Sanjuán; Jorge Gayoso; Santiago Gil; Elena Ruíz; Ann Margaret Little; Alasdair McWhinnie; Alejandro Madrigal Journal: Exp Hematol Date: 2003-06 Impact factor: 3.084
Authors: U Sobol; A Go; S Kliethermes; S Bufalino; T Rodriguez; S Smith; M Parthasarathy; P Stiff Journal: Bone Marrow Transplant Date: 2015-09-14 Impact factor: 5.483
Authors: Mark van der Garde; Anneke Brand; Manon C Slot; Alice de Graaf-Dijkstra; Jaap Jan Zwaginga; Yvette van Hensbergen Journal: Stem Cells Dev Date: 2015-03-13 Impact factor: 3.272
Authors: Andromachi Scaradavou; Claudio G Brunstein; Mary Eapen; Jennifer Le-Rademacher; Juliet N Barker; Nelson Chao; Corey Cutler; Colleen Delaney; Fangyu Kan; Luis Isola; Chatchada Karanes; Mary J Laughlin; John E Wagner; Elizabeth J Shpall Journal: Blood Date: 2012-12-09 Impact factor: 22.113